The Management of Epilepsy in the 1990s: Acquisitions, Uncertainties and Priorities for Future Research

Drugs

Volumn 49, Issue 5, 1995, Pages 680-694

  Beghi, Ettore ^a,b   Perucca, Emilio ^c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENCE; ADOLESCENT; ADULT; APLASTIC ANEMIA; CHILD; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG WITHDRAWAL; EPILEPSY; FOCAL EPILEPSY; GENERALIZED EPILEPSY; GRAND MAL EPILEPSY; HUMAN; HYPONATREMIA; INFANT; INFANTILE SPASM; LENNOX GASTAUT SYNDROME; LIVER TOXICITY; PATIENT MONITORING; PROGNOSIS; RECURRENCE RISK; REVIEW; RISK FACTOR; SIDE EFFECT;

ALGORITHMS; ANTICONVULSANTS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EPILEPSY; HUMAN; SUPPORT, NON-U.S. GOV'T; TREATMENT FAILURE;

EID: 0028915864     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199549050-00004     Document Type: Article

References (112)

1. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review
2. Epilepsy after a first unprovoked seizure in childhood
3. The risk of recurrence of nonfebrile seizures in children
4. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-84
5. Studies on convulsive disorders in young children: I
6. Risk of recurrence after an initial unprovoked seizure
7. The first seizure in adult life: value of clinical features, electroencephalography and computerized tomographic scaning in prediction of seizure recurrence
8. Seizure recurrence after a 1st unprovoked seizure: an extended follow-up
9. The risk of recurrence following a first unprovoked seizure in childhood: a prospective study
10. Idiopathic first seizure in adult life: who should be treated?
11. Risk of recurrence after a single unprovoked generalized tonic-clonic seizure
12. National general practice study of epilepsy: recurrence after a first seizure
13. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures
14. Adverse reactions to antiepileptic drugs: a multicenter survey of clinical practice
15. Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure
16. A randomized study of carbamazepine versus no medication after a first unprovoked seizure in childhood
17. Effect of antiepileptic treatment initiated after the first unprovoked seizure on the long-term prognosis of epilepsy
18. Postraumatic epilepsy
19. Post-traumatic seizures
20. Prevention of post-traumatic epilepsy
21. Monotherapy or polytherapy for epilepsy?
22. Drug treatment of epilepsy
23. Historical perspective on the choice of antiepileptic drugs for the treatment of seizures in adults
24. Standard approach to antiepileptic drug treatment in the United Kingdom
25. Standard approach to antiepileptic drug treatment in the United States
26. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal)
27. Valproic acid versus ethosuximide in the treatment of absence seizures
28. A comparison of phenytoin and valproate in previously untreated adult epileptic patients
29. Which drug for the adult epileptic patients: phenytoin or valproate?
30. The comparative efficacy of antiepileptic drugs for partial and tonic-clonic seizures
31. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy
32. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic/clonic seizures in adults
33. Comprehensive primary health care antiepileptic drug treatment programme in rural and semi-urban Kenya
34. A multicentre comparative trial of sodium valproate and carbamazepine in adult-onset epilepsy
35. Clinical pharmacology and medical treatment
36. How to use antiepileptic drugs
37. Natural history and prognosis of epilepsy: report of a multi-institutional study in Japan
38. Prognosis of childhood epilepsy
39. Epileptic patients who are refractory to anticonvulsant medications
40. The late prognosis of epilepsy in childhood: results of a prospective follow-up study
41. Prognosis of epilepsy in newly referred patients: a multicenter prospective study of the effects of monotherapy on the long-term course of epilepsy
42. A prospective study of infantile spasms: clinical and therapeutic correlations
43. Long-term prognosis of convulsive disorders in the first year of life: mental and physical development and seizure persistence
44. Classifications of epileptic syndromes: advantages and limitations for evaluation of childhood epileptic syndromes in clinical practice
45. Recipes for clinical practice
46. Neurological diseases
47. Why does epilepsy become intractable?
48. Unnecessary polypharmacy for epilepsy
49. Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine
50. Antiepileptic drug withdrawal in childhood epilepsy: preliminary results of a prospective study
51. The influence of seizure type on the efficacy of plasma concentrations of phenytoin, phenobarbital and carbamazepine
52. The prognosis for seizure control in newly diagnosed epilepsy
53. The course of untreated epilepsy
54. A permanent change in brain function resulting from daily electrical stimulation
55. Some aspects of prognosis in the epilepsies: a review
56. Remission of seizures and relapse in patients with epilepsy
57. Epileptic seizures in a population of 6000
58. The natural history of untreated epilepsy in a rural community in Africa
59. Proposal for revised classification of epilepsies and epileptic syndromes
60. Chronic epilepsy
61. Antiepileptic drugs: clinical aspects
62. Pharmacokinetic optimisation of anticonvulsant therapy
63. Overuse of monitoring of blood concentrations of antiepileptic drugs
64. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs
65. Place of newer antiepileptic drugs in the treatment of epilepsy
66. Zonisamide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy
67. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control
68. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy
69. How often is medication taken as prescribed?
70. Carbamazepine vs diphenyl-hydantoin vs their combination in adult epilepsy
71. Valproate ethosuximide combination therapy for refractory absence seizures
72. Two antiepileptic drugs for intractable epilepsy with complex partial seizures
73. Controlled trials in epilepsy: a review
74. The clinical pharmacology of new antiepileptic drugs
75. Developments in antiepileptic drug therapy
76. Overtreatment with antiepileptic drugs: how extensive is the problem?
77. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?
78. Mechanism of action of new anticonvulsant drugs
79. New antiepileptic drugs: from serependity to rational discovery
80. Combined gammavinyl GABA (vigabatrin) and lamotrigine therapy in management of refractory epilepsy
81. Vigabatrin and lamotrigine in refractory epilepsy
82. Interaction of lamotrigine with sodium valproate
83. Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy
84. Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders
85. New antiepileptic agents: a review of their current status and clinical potential
86. The use of new anticonvulsant drugs in children
87. Vigabatrin
88. Lamotrigine
89. Lamotrigine
90. Oxcarbazepine
91. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut Syndrome)
92. Felbamate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy
93. Vigabatrin in infantile spasms — why add-on?
94. A practical guide to discontinuing antiepileptic drugs
95. Discontinuing antiepileptic drugs
96. When do epileptic patients need treatment? Starting and stopping medication
97. Suppression of antiepileptic treatment
98. Relapse following discontinuation of antiepileptic drugs: a meta-analysis
99. Discontinuing antiepileptic medication in children with epilepsy after two years without seizures
100. Withdrawal of anticonvulsant drugs in patients free of seizures for two years
101. Randomized study of antiepileptic drug withdrawal in patients in remission
102. Discontinuing antiepileptic drugs in children with epilepsy: a prospective study
103. Stopping medication in children with epilepsy
104. Discontinuation of antiepileptic therapy: a prospective study in children
105. Discontinuing antiepileptic drugs in children with epilepsy
106. Follow-up of 146 children with epilepsy after withdrawal of antiepileptic therapy
107. Le epilessie nell’infanzia: diagnosi e terapia